2025-11-13T21:10:50+00:00 2024-12-31 350921680 CROWE LLP 575 Market Street Suite 3300 San Francisco CA 941055829 990 2024-01-01 841327507 Allosource ALLO 7208730213 6278 S TROY CIRCLE CENTENNIAL CO 80111 Yan Deng CHIEF FINANCIAL OFFICER 7208730213 2025-11-14 true DIANE KIRMACI P01578407 4155761100 2025-11-14 2024 2025-03-06 01:10:19Z Dean Elliott 6278 S TROY CIRCLE CENTENNIAL CO 80111 180123255 false X HTTPS://ALLOSOURCE.ORG/ X 1994 IL ALLOSOURCE RESPONSIBLY PROCESSES AND DISTRIBUTES HUMAN DONATED TISSUE THAT ENHANCES AND SAVES LIVES. 6 5 611 5 0 790852 770680 172567159 177886424 -1128677 408668 519745 989201 172749079 180054973 346328 262167 0 57414966 56158700 0 0 116140405 118386213 173901699 174807080 -1152620 5247893 152171181 150410958 55800798 48056569 96370383 102354389 INSPIRED BY THE GIFT OF DONATION FROM OUR COMMUNITIES, ALLOSOURCE RESPONSIBLY PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. false false 156469437 178858828 PROCESSING AND DISTRIBUTION: WITH THE GIFT OF DONATED TISSUE, ALLOSOURCE PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. IN 2024, ALLOSOURCE FULFILLED THIS RESPONSIBILITY BY PROCESSING MORE THAN 7,200 DONORS, AND DISTRIBUTED THE TISSUE THROUGHOUT NORTH AMERICA, SOUTH AMERICA, CARIBBEAN, EUROPE, MIDDLE EAST, ASIA AND AFRICA. MUSCULOSKELETAL AND SOFT TISSUE DONORS PROVIDE AN OPPORTUNITY TO CREATE LIFE-SAVING AND LIFE-ENHANCING SOLUTIONS IN ORTHOPEDIC, SPINE, BURN, AND WOUND PROCEDURES TO HELP RESTORE PATIENT HEALTH AND MOBILITY. ALLOSOURCE IS ACCREDITED BY THE AMERICAN ASSOCIATION OF TISSUE BANKS AND IS REGISTERED WITH THE FDA. 6183879 RESEARCH, EDUCATION, AND TRAINING: ALLOSOURCE IS DEDICATED TO ADVANCING THE USE OF TRANSPLANTABLE ALLOGENEIC CELLS AND TISSUE THROUGH PIONEERING RESEARCH. IN 2024, ALLOSOURCE CONTINUED ITS RESEARCH IN THE AREAS OF PEDIATRIC ORTHOPEDICS AND CELLULAR THERAPIES, EXPANDING THE IMPACT OF DONATION BY FINDING ADDITIONAL USES FOR TISSUE. ALLOSOURCE WORKED WITH THE 501(C)(3) ORGANIZATIONS THAT RECOVER TISSUE TO REDUCE TISSUE CONTAMINATION. WE ALSO PROVIDED EDUCATIONAL OPPORTUNITIES TO OUR PARTNER ORGAN PROCUREMENT ORGANIZATIONS TO HELP THEM INCREASE DONATION RATES IN THEIR RESPECTIVE COMMUNITIES. 262167 262167 CHARITABLE CONTRIBUTION ACTIVITY: IN ALIGNMENT WITH OUR MISSION, ALLOSOURCE PROVIDED GRANTS TO SUPPORT 501(c)(3) ORGANIZATIONS THAT ARE INVOLVED IN ORGAN, EYE, AND TISSUE DONATION, S.T.E.M. EDUCATION, AS WELL AS PATIENT PHYSICAL AND MENTAL HEALING. IN 2024, ALLOSOURCE GAVE GRANTS TO THREE ORGANIZATIONS TO FURTHER TISSUE DONATION AND TRANSPLANTATION AWARENESS AND PROCESSES AND MADE CHARITABLE CONTRIBUTIONS TO SIX OTHER 501(C)(3) ORGANIZATIONS THROUGH DIRECT AND MATCHING EMPLOYEE FINANCIAL DONATIONS. 162915483 true true false true false false false false false false true false false false true false false true false false true false false false false false false true false true true false false false false false false false false false false false false false false false false false false false false true 142 0 true 611 true false false false false false false false false false false false false X 6 5 false false false false true true false true false false false false true true true true true true true true false false CA IL NY X YAN DENG 7208730213 6278 S TROY CIRCLE CENTENNIAL CO 80111 DEAN H ELLIOTT PRESIDENT, CEO 40.0 X X 754854 0 70326 JENNIFER PRINZ BOARD MEMBER - CHAIR 3.0 X X 0 0 0 MARK SIMON BOARD MEMBER - VICE CHAIR 3.0 X X 0 0 0 SUZANNE CONRAD BOARD MEMBER - TREASURER 3.0 X X 0 0 0 DR HARRY WILKINS BOARD MEMBER 3.0 X 0 0 0 KEVIN LEE BOARD MEMBER 3.0 X 0 0 0 KEVIN L WHITTEN CHIEF COMMERCIAL OFFICER 40.0 X 324650 0 61203 YAN DENG CHIEF FINANCIAL OFFICER 40.0 X 348762 0 56322 BRIAN R BOBKA VP INTERNATIONAL 40.0 X 284474 0 42443 KENNETH HAMMONS SVP OPERATIONS 40.0 X 331147 0 47120 KIMBERLY MEYER SVP QUALITY & PERFORMANCE EXCELLENCE 40.0 X 261271 0 52984 MICHELLE ZEPPELIN SVP HUMAN RESOURCES 40.0 X 256157 0 37574 ANDREA HO ASSOCIATE MEDICAL DIRECTOR 40.0 X 256935 0 28701 ANDREW ABELL HEAD STRATEGIC ACCOUNTS 40.0 X 262571 0 20389 CAROLYN RORICK SR DIRECTOR PRODUCT DEVELOPMENT INNOVATION & CLINICAL AFFAIRS 40.0 X 252858 0 45652 HANNIS W THOMPSON III MEDICAL DIRECTOR 40.0 X 319169 0 26907 INGA GUREVICH ASSOCIATE MEDICAL DIRECTOR 40.0 X 259938 0 25570 THOMAS A CYCYOTA Former President 0.0 X 668532 0 231 4581318 0 515422 132 true true false EUROFINS DPT PO BOX 84900 CHICAGO IL 60689 LABORATORY SERVICE 4013109 FEDERAL EXPRESS CORPORATION PO BOX 94515 PALATINE IL 60094 SHIPPING SERVICE 2578683 NORTH AMERICAN SCIENCE ASSOC PO BOX 735220 CHICAGO IL 60673 BIOASSAY TESTING 1822245 HEATH DUFFY 11524 ZINFANDEL AVE NE ALBUQUERQUE NM 87122 DISTRIBUTOR COMMISSIONS 1622897 STRYKER SPORTS MEDECINE 5900 OPTICAL COURT SAN JOSE CA 95138 DISTRIBUTOR COMMISSIONS 1373967 57 770680 0 770680 TISSUE DISTRIBUTION & PROCESSING 900099 177886424 177886424 0 0 0 0 177886424 367492 367492 0 0 109458 0 0 68282 109458 -68282 41176 41176 INCOME (LOSS) FROM JRF 900099 972404 972404 0 0 Other income 900099 16797 16797 0 0 0 0 989201 180054973 178858828 0 425465 262167 262167 3598050 2887827 710223 0 44041508 38356004 5685504 257248 100521 156727 4884571 4234465 650106 3377323 2942188 435135 701682 350841 350841 1094362 1094362 12981 9736 3245 991247 712102 279145 0 94788 94788 1141724 957050 184674 1407459 1048728 358731 1579232 1579232 1914983 1485139 429844 815022 789255 25767 283097 73418 209679 768542 691688 76854 4072506 3940691 131815 598263 448697 149566 TISSUE PROCESSING COSTS 86290913 86290913 COST OF DISTRIBUTION 11239992 11239992 REPAIRS & MAINTENANCE 2625141 2496427 128714 LICENSE FEES 1708332 1566822 141510 1045947 451580 594367 0 174807080 162915483 11891597 0 191135 2200571 12484940 13698011 0 22465805 22883785 0 0 0 0 0 69541032 65102810 775264 1451059 81653625 48193207 35199134 33460418 0 3618652 3618652 5246402 6218806 10897 0 2637920 1776846 152171181 150410958 34412671 33586236 0 0 11630574 9598591 0 0 0 7951414 3823367 0 1806139 1048375 55800798 48056569 X 96370383 102354389 0 0 0 0 96370383 102354389 152171181 150410958 5247893 736113 0 X false true true false X 546574 8425622 217852 790852 770680 10751580 134116779 147038805 156687598 172567159 177886424 788296765 0 0 0 134663353 155464427 156905450 173358011 178657104 799048345 10336850 10413568 8296127 9072508 8874959 46994012 67676533 67695468 70890213 69626814 68036708 343925736 78013383 78109036 79186340 78699322 76911667 390919748 408128597 538846 362398 320747 333089 476950 2032030 0 538846 362398 320747 333089 476950 2032030 0 0 0 801575 -41691 -36308 519745 989201 2232522 136003774 155785134 157189889 174210845 180123255 803312897 0.50806 0.51929 0 0.0 X Schedule A, Part III, Line 12 Other Income DESCRIPTION - INCOME FROM JRF, COLUMN A - 801575.0, COLUMN B - -41691.0, COLUMN C - -36308.0, COLUMN D - 519745.0, COLUMN E - 972404.0, COLUMN F - 2215725.0; DESCRIPTION - OTHER INCOME, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 16797.0, COLUMN F - 16797.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false true 12981 false false false 12981 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY ALLOSOURCE DOES NOT MAKE POLITICAL CAMPAIGN DONATIONS. THE ORGANIZATION INDIRECTLY PARTICIPATED IN LOBBYING ACTIVITIES THROUGH MEMBERSHIP FEES PAID TO THE AMERICAN ASSOCIATION OF TISSUE BANKS AND THE COLORADO BIOSCIENCE ASSOCIATION. 2076368 2076368 51179535 26061598 25117937 11659 11659 0 18092168 14131975 3960193 10293895 7987975 2305920 33460418 Federal Income Taxes DEFERRED COMPENSATION 567495 Operating Lease Liability 480880 1048375 Europe (Including Iceland and Greenland) 0 0 Program Services Tissue Distribution 9804 Middle East and North Africa 0 0 Program Services Tissue Distribution South America 0 0 Program Services Tissue Distribution 923 Central America and the Caribbean 0 0 Program Services TISSUE DISTRIBUTION East Asia and the Pacific 0 0 Program Services TISSUE DISTRIBUTION 3864 North America (Canada & Mexico only) 0 0 Program Services TISSUE DISTRIBUTION 0 0 0 0 0 0 14591 0 14591 false false false false false true Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual true The Phoenix Society 1835 R W Berends Dr SW Grand Rapids MI 49519 232062352 501(C)(3) 100000 TO SUPPORT MISSION Donate Life New York State 185 Jordan Road Troy NY 12180 510430374 501(C)(3) 35000 TO SUPPORT MISSION Limb Preservation Foundation 1600 Broadway St Ste 2400 Denver CO 80202 841565464 501(C)(3) 33600 TO SUPPORT MISSION Chicago Sports Summit Foundation One Westbrook Corporate Center Ste Westchester IL 60154 371853214 501(C)(3) 5000 TO SUPPORT MISSION Arrupe Coporate Work Study Program 4343 Utica St Denver CO 80212 460508814 501(C)(3) 5640 TO SUPPORT MISSION Donor Alliance Inc 200 Spruce St 200 Denver CO 80230 841003771 501(C)(3) 6810 TO SUPPORT MISSION Network of Hope 615 Elsinore Place Cincinnati OH 45202 611122515 501(C)(3) 10000 TO SUPPORT MISSION Mercy Ship Warehouse 15862 State Hwy 110 N Lindale TX 75771 262414132 501(C)(3) 32675 FMV TISSUE DONATION TO SUPPORT MISSION Ghana Make A Difference PO Box 55 Star ID 83669 455615778 501(C)(3) 32192 FMV TISSUE DONATION TO SUPPORT MISSION 9 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds THE CEO COMMUNICATES ON AN ON-GOING BASIS WITH RECIPIENTS OF GRANT FUNDS TO ENSURE THE OBJECTIVES AND GOALS OF THESE PROGRAMS ARE FULFILLED. X X X X X X false true false true false false false false false THOMAS A CYCYOTA Former President 5460 0 0 0 663072 0 195 0 36 0 668763 0 663072 0 DEAN H ELLIOTT PRESIDENT, CEO 509026 0 82614 0 163214 0 53165 0 17161 0 825180 0 161613 0 KEVIN L WHITTEN CHIEF COMMERCIAL OFFICER 275352 0 47436 0 1862 0 37042 0 24161 0 385853 0 0 0 YAN DENG CHIEF FINANCIAL OFFICER 297186 0 51045 0 531 0 38211 0 18111 0 405084 0 0 0 BRIAN R BOBKA VP INTERNATIONAL 218756 0 45654 0 20064 0 27472 0 14971 0 326917 0 18437 0 KENNETH HAMMONS SVP OPERATIONS 281565 0 47620 0 1962 0 33490 0 13630 0 378267 0 0 0 KIMBERLY MEYER SVP QUALITY & PERFORMANCE EXCELLENCE 222278 0 38723 0 270 0 28964 0 24020 0 314255 0 0 0 MICHELLE ZEPPELIN SVP HUMAN RESOURCES 218989 0 36787 0 381 0 27623 0 9951 0 293731 0 0 0 HANNIS W THOMPSON III MEDICAL DIRECTOR 237211 0 44335 0 37623 0 8697 0 18210 0 346076 0 36387 0 ANDREA HO ASSOCIATE MEDICAL DIRECTOR 230520 0 25641 0 774 0 4717 0 23984 0 285636 0 0 0 ANDREW ABELL HEAD STRATEGIC ACCOUNTS 173655 0 0 0 88916 0 8086 0 12303 0 282960 0 0 0 INGA GUREVICH ASSOCIATE MEDICAL DIRECTOR 233744 0 25006 0 1188 0 7814 0 17756 0 285508 0 0 0 CAROLYN RORICK SR DIRECTOR PRODUCT DEVELOPMENT INNOVATION & CLINICAL AFFAIRS 215006 0 37648 0 204 0 27598 0 18054 0 298510 0 0 0 Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Following individuals participated in a supplemental executive retirement plan in 2024 sponsored by AlloSource: Dean Elliot - $49,100, Yan Deng - $29,000, Kevin Whitten - $26,950, Ken Hammons - $25,000, Kimberly Meyer - $22,000, Brian Bobka - $21,238, Carolyn Rorick - $21,000, and Michelle Zeppelin - $20,900. The Dollar amount represents the current year Contribution made by AlloSource on behalf of the individuals to the plan in 2024. This information is included in reportable compensation on the form 990, part VII and Schedule J, part II. The Following individuals also participated in a supplemental executive retirement plan in 2024 sponsored by AlloSource: Tom Cycyota - $663,072, Dean Elliot - $161,613, Brian Bobka - $18,437, Hannis Thompson - $36,387. The Dollar amount represents the current year Distribution made by the plan to the individuals. This information is included in reportable compensation on the form 990, part VII and Schedule J, part II. Schedule J, Part I, Line 5a Compensation contingent on revenues of the organization The Sales department has revenue performance as one of their commission plan components. A COLORADO HEALTH FACILITIES AUTHORITY REV 840752932 000000000 2010-12-29 22881000 Refund 2006 & 2007 Bonds, Finance New Administration Building false false false B COLORADO HEALTH FACILITIES AUTHORITY REV 840752932 000000000 2015-02-12 9108000 FUNDING FOR FACILITY EXPANSION false false false A 16676000 0 22881000 0 0 0 247691 0 0 6800729 15832580 0 2012 true false true true B 5658425 0 9108000 0 0 0 50001 0 0 9057999 0 0 2015 false false true true A false false false false false false 0.0 0.0 0.0 false false 0 false true B false false false false false false 0.0 0.0 0.0 false false 0 false true A false false true false true false 0 false false false 0 false false true B false false true false false false 0 false false false 0 false false true A true B true Schedule K, Part I BOND ISSUES AN AGREEMENT WAS PUT IN PLACE WITH THE ISSUER AT THE TIME THE BONDS WERE ISSUED WITH RESPECT TO PERMITTED USE OF BOND-FINANCED ASSETS AND REMEDIAL ACTIONS UNDER TREAS. REG. SS 1.145-2(A) AND 1.141-12 THAT WILL BE UNDERTAKEN IF THERE IS AN IMPERMISSIBLE CHANGE IN USE OF SUCH ASSETS. ADDITIONALLY, THE ALLOSOURCE BOARD OF DIRECTORS HAS ADOPTED A RESOLUTION EFFECTIVE JULY 31, 2012, ESTABLISHING PROCEDURES TO ENSURE ANY VIOLATIONS THAT CANNOT BE "SELF-CORRECTED" UNDER TREAS. REG. SS 1.141-12 WILL BE REMEDIATED THROUGH THE IRS'S VOLUNTARY CLOSING AGREEMENT PROGRAM AS DESCRIBED IN NOTICE 2008-31. Form 990, Part VI, Line 6 Classes of members or stockholders THE ORGANIZATION HAS ONE CLASS OF MEMBERSHIP. EACH CORPORATE MEMBER IS A 501 (c)(3), TAX EXEMPT ORGANIZATION. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body EACH CORPORATE MEMBER HAS THE EXECUTIVE POWER TO ELECT AND REMOVE, WITH OR WITHOUT CAUSE, ONE OF THE VOTING DIRECTORS OF THE CORPORATION, EXCLUDING EX-OFFICIO VOTING DIRECTORS. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body THE ORGANIZATION DOES NOT HAVE ANY COMMITTEES WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS REVIEWED BY THE ORGANIZATION'S KEY OFFICERS FOR BOTH DESCRIPTION AND NUMERIC CONTENT. THE FORM IS THEN REVIEWED BY OUTSIDE COUNSEL. AFTER THESE REVIEWS, THE FORM IS SENT TO THE AUDIT COMMITTEE FOR A DETAILED REVIEW AND OPPORTUNITY TO PROVIDE COMMENTS AND RECOMMENDATIONS TO MANAGEMENT. SUBSEQUENT TO INCORPORATION OF THE AUDIT COMMITTEE RECOMMENDATION INTO THE FORM 990, THE COMMITTEE ADOPTS A RESOLUTION TO RECOMMEND THE FORM 990 TO THE BOARD, AT WHICH TIME THE FORM 990 IS SUBMITTED TO THE BOARD FOR REVIEW AND ACCEPTANCE. Form 990, Part VI, Line 12c Conflict of interest policy THE ORGANIZATION MONITORS THE POLICY BY REVIEWING THE ANNUAL CONFLICT OF INTEREST POLICY STATEMENTS RECEIVED FROM ITS DIRECTORS, OFFICERS AND KEY EMPLOYEES IN ACCORDANCE WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. IN CONNECTION WITH ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST, AN INTERESTED PERSON IMMEDIATELY MUST DISCLOSE IN WRITING OR AT A NOTICED MEETING OF THE BOARD OF DIRECTORS THE EXISTENCE AND NATURE OF THE CONFLICT AND OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OF DIRECTORS. IN ALL EVENTS, SUCH WRITTEN DISCLOSURE MUST BE MADE IN SUFFICIENT TIME TO PERMIT THE BOARD, WHILE CONSIDERING THE PERTINENT ALLOSOURCE BUSINESS ACTIVITY, TO CONSIDER THE DISCLOSURE, MAKE NECESSARY OR APPROPRIATE INQUIRY, AND TAKE SUITABLE ACTION IN RESPECT TO AND IN LIGHT OF THE DISCLOSURE. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS. AFTER DISCLOSURE OF THE ACTUAL OR POTENTIAL CONFLICT OF INTEREST IN FULL DETAIL, THE INTERESTED PERSON SHALL LEAVE THE BOARD MEETING WHILE THE QUESTION OF THE EXISTENCE AND MATERIALITY OF THE DISCLOSED CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON BY THE REMAINING BOARD MEMBERS PRESENT AT THE MEETING. NO SUCH DEPARTURE BY A DISCLOSING INTERESTED PERSON SHALL DEFEAT THE EXISTENCE OF A QUORUM TO CONDUCT THE BUSINESS UNDER CONSIDERATION. THE REMAINING BOARD MEMBERS SHALL DECIDE BY MAJORITY VOTE, UNLESS OTHERWISE PRESCRIBED BY THE BYLAWS, WHETHER A CONFLICT OF INTERST EXISTS AND, IF A CONFLICT DOES EXIST, WHETHER IT IS MATERIAL AND THEREFORE IMPERMISSIBLE CONDUCT FOR THE DISCLOSING INTERESTED PERSON. THE CHAIRPERSON OF THE BOARD OF DIRECTORS SHALL, IN HIS OR HER DISCRETION APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE THE IMPACT OF THE DISCLOSED CONFLICT IN THE CONTEXT OF THE PROPOSED TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT. AFTER EXERCISING DUE DILIGENCE IN SUCH INVESTIGATION, THE BOARD SHALL DETERMINE WHETHER ALLOSOURCE MAY ACHIEVE A MORE ADVANTAGEOUS TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT WITH REASONABLE EFFORT, FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION, ARRANGEMENT BUSINESS RELATIONSHIP, OR CONTRACT MAY NOT REASONABLY BE ACHIEVED UNDER CIRCUMSTANCES WHICH WOULD AVOID THE CONFLICT OF INTEREST, THE BOARD SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT IS IN ALLOSOURCE'S BEST INTEREST AND WHETHER THE RESULT IS FAIR AND REASONABLE TO ALLOSOURCE, NOTWITHSTANDING THE CONFLICT OF INTEREST. THE BOARD ALSO SHALL EVALUATE THE POSSIBLE APPEARANCE OF IMPROPRIETY AND POTENTIAL FOR ADVERSE IMPACT ON DONATION IN ITS DELIBERATIONS. THE BOARD SHALL BE GUIDED IN ITS DECISION BY THE PRINCIPLES ARTICULATED ABOVE. IF THE BOARD HAS REASONABLE CAUSE TO BELIEVE THAT AN INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, IT SHALL INFORM THE INTERESTED PERSON OF THE BASIS FOR THE BOARD'S BELIEF AND AFFORD THE INTERESTED PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE FROM THE INTERESTED PERSON AND MAKING SUCH FURTHER INVESTIGATION AS THE BOARD MAY WISH THE BOARD DETERMINES THAT THE INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, THE BOARD SHALL TAKE ANY DISCIPLINARY AND CORRECTIVE ACTION IT DEEMS APPROPRIATE, INCLUDING RECOMMENDATION TO THE CORPORATE MEMBER THAT THE INTERESTED PERSON, IF A DIRECTOR OF ALLOSOURCE, BE REMOVED OR EXPELLED BY FURTHER ACTION OF THE PERTINENT CORPORATE MEMBER PURSUANT TO THE ALLOSOURCE BYLAWS, EXPULSION OF AN INTERESTED PERSON OTHER THAN A DIRECTOR, AND PURSUIT OF A CLAIM FOR RESTITUTION OR DAMAGES, AS THE BOARD MAY DECIDE. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE PROCESS FOR SETTING COMPENSATION FOR THE CEO BEGINS BY ESTABLISHING GOALS AND OBJECTIVES EACH YEAR. THE BOARD OF DIRECTORS EVALUATES THIS POSITION'S PERFORMANCE TO THE GOALS AND OBJECTIVES FOR PERFORMANCE EVALUATIONS. THE CEO'S PERFORMANCE, ALONG WITH BENCHMARK DATA SUPPLIED FROM A THIRD-PARTY ON COMPARABLE SALARIES AND BENEFIT PACKAGES, ARE UTILIZED TO ARRIVE AT THE CEO'S COMPENSATION. THIS PROCESS AND A REASONABLENESS REVIEW CONDUCTED BY THE BOARD OF DIRECTORS WAS LAST COMPLETED IN 2024. Form 990, Part VI, Line 15b Process to establish compensation of other employees FOR THE CHIEF FINANCIAL OFFICER, CHIEF COMMERCIAL OFFICER, THE PERFORMANCE ALONG WITH BENCHMARK DATA SUPPLIED FROM A THIRD-PARTY ON COMPARABLE SALARIES AND BENEFIT PACKAGES, ARE UTILIZED TO ARRIVE AT THEIR COMPENSATION. THIS PROCESS AND A REASONABLENESS. Form 990, Part VI, Line 19 Required documents available to the public THE GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION AT THE ORGANIZATION'S OFFICE IN CENTENNIAL, COLORADO, ALONG WITH THE ORGANIZATION'S EXEMPTION APPLICATION, FORM 1023. THE CONFLICT OF INTEREST POLICY IS NOT MADE AVAILABLE FOR PUBLIC INSPECTION. THE FINANCIAL STATEMENTS ARE AUDITED BY INDEPENDENT ACCOUNTANTS. THE FINANCIAL STATEMENTS INCLUDE THE STATEMENT OF REVENUE AND EXPENSES AND BALANCE SHEET, AND ARE REPORTED ON THE ORGANIZATION'S FORM 990 IN PARTS VIII, IX, AND X, AND SCHEDULE D. THE FORM 990 AND SCHEDULES ARE MADE AVAILABLE UPON REQUEST AT THE OFFICE OF THE ORGANIZATION IN CENTENNIAL, COLORADO.